Dr. Roger D. Kornberg Ph.D. Net Worth

Dr. Roger D. Kornberg Ph.D. biography

Dr. Roger D. Kornberg Ph.D. is the Co-Founder, Chairman & Scientific Advisory Board and Chief Scientist at Cocrystal Pharma Inc.

What is the salary of Dr D?

As the Co-Founder and Chairman & Scientific Advisory Board and Chief Scientist of Cocrystal Pharma Inc, the total compensation of Dr D at Cocrystal Pharma Inc is $75,000. There are 6 executives at Cocrystal Pharma Inc getting paid more, with James J. Martin CPA, CPA, M.B.A., MBA having the highest compensation of $331,000.

How old is Dr D?

Dr D is 74, he's been the Co-Founder and Chairman & Scientific Advisory Board and Chief Scientist of Cocrystal Pharma Inc since . There are 1 older and 9 younger executives at Cocrystal Pharma Inc. The oldest executive at Cocrystal Pharma Inc is Phillip Frost, 83, who is the Independent Director.

What's Dr D's mailing address?

Roger's mailing address filed with the SEC is 945, Concord Street, Framingham, Middlesex County, Massachusetts, 01701, United States.

Insiders trading at Cocrystal Pharma Inc

Over the last 10 years, insiders at Cocrystal Pharma Inc have traded over $2,664,250 worth of Cocrystal Pharma Inc stock and bought 23,366,560 units worth $16,815,201 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Phillip Md Et Al Frost, and Jane Ph D Hsiao. On average, Cocrystal Pharma Inc executives and independent directors trade stock every 113 days with the average trade being worth of $1,616,422. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 4 April 2023, trading 1,015,229 units of COCP stock currently worth $2,000,001.

What does Cocrystal Pharma Inc do?

cocrystal (otcqb:cocp) is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. cocrystal employs unique technologies and nobel prize winning expertise to create first- and best-in-class antiviral drugs. these technologies, including our nucleoside chemistry expertise and market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. the company has identified promising, preclinical stage antiviral compounds for the unmet medical needs including hepatitis, influenza and norovirus infections. cocrystal has previously received strategic investments from teva pharmaceuticals, opko health (opk), dr. raymond schinazi, brace pharmaceutical, llc, and the frost group.

Cocrystal Pharma Inc executives and stock owners

Cocrystal Pharma Inc executives and other stock owners filed with the SEC include:

• James J. Martin CPA, CPA, M.B.A., MBA,
  Interim Co-CEO, CFO & Corp. Sec.
• Dr. Sam Lee,
  Co-Founder & Pres
• Sam Lee,
  President
• James J. Martin CPA, M.B.A., CPA, MBA,
  CFO & Corp. Sec.
• James Martin,
  Chief Financial Officer
• Gary Wilcox,
  Chairman of the Board, Chief Executive Officer
• Dr. Roger D. Kornberg Ph.D.,
  Co-Founder, Chairman & Scientific Advisory Board and Chief Scientist
• Jenene Thomas,
  IR Contact Officer
• Steven Rubin,
  Independent Director
• Anthony Japour,
  Independent Director
• Phillip Frost,
  Independent Director
• Roger Kornberg,
  Director
• Richard C Jr Pfenniger,
  Director
• Jane Ph D Hsiao,
  
• David S Block,
  
• Gerald A Mc Guire,
  CHIEF FINANCIAL OFFICER
• Jeffrey A Meckler,
  
• Douglas L Mayers,
  CHIEF MEDICAL OFFICER
• Curtis Dale,
  INTERIM CFO
• Walt Addison Linscott,
  GENERAL COUNSEL AND SECRETARY
• Raymond F Schinazi,
  10% owner
• Phillip Md Et Al Frost,
  Director
• Fred Hassan,
  Director